Goldman Sachs analyst Salveen Richter has maintained their bullish stance on BIIB stock, giving a Buy rating on November 22.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Salveen Richter has given his Buy rating due to a combination of factors influencing Biogen’s market position. The discontinuation of Novo Nordisk’s semaglutide trials in Alzheimer’s disease has removed a significant competitive threat, as the trials did not show superiority over the placebo. This development alleviates potential demand challenges for Biogen’s anti-amyloid treatments, which are not affected by the same imaging abnormalities as semaglutide.
Furthermore, Biogen’s Leqembi is expected to gain traction in 2026, supported by advancements in blood-based diagnostics and the launch of subcutaneous maintenance treatments. Additional catalysts include potential positive outcomes from Lilly’s Alzheimer’s study and promising mid-2026 data for Biogen’s tau-targeting BIIB080. Beyond Alzheimer’s, Biogen’s pipeline in other areas, such as lupus, is anticipated to gain recognition with upcoming trial readouts, further supporting the Buy rating.
In another report released on November 22, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $168.00 price target.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BIIB in relation to earlier this year.